Division of Nephrology, Department of Internal Medicine, University of Michigan Medical School, Ann Arbor, Michigan, USA.
Department of Statistics, University of Michigan, Ann Arbor, Michigan, USA.
JCI Insight. 2019 Nov 1;4(21):130317. doi: 10.1172/jci.insight.130317.
BACKGROUNDIn this study, we identified the lipidomic predictors of early type 2 diabetic kidney disease (DKD) progression, which are currently undefined.METHODSThis longitudinal study included 92 American Indians with type 2 diabetes. Serum lipids (406 from 18 classes) were quantified using mass spectrometry from baseline samples when iothalamate-based glomerular filtration rate (GFR) was at least 90 mL/min. Affymetrix GeneChip Array was used to measure renal transcript expression. DKD progression was defined as at least 40% decline in GFR during follow-up.RESULTSParticipants had a mean age of 45 ± 9 years and median urine albumin/creatinine ratio of 43 (interquartile range 11-144). The 32 progressors had significantly higher relative abundance of polyunsaturated triacylglycerols (TAGs) and a lower abundance of C16-C20 acylcarnitines (ACs) (P < 0.001). In a Cox regression model, the main effect terms of unsaturated free fatty acids and phosphatidylethanolamines and the interaction terms of C16-C20 ACs and short-low-double-bond TAGs by categories of albuminuria independently predicted DKD progression. Renal expression of acetyl-CoA carboxylase-encoding gene (ACACA) correlated with serum diacylglycerols in the glomerular compartment (r = 0.36, and P = 0.006) and with low-double-bond TAGs in the tubulointerstitial compartment (r = 0.52, and P < 0.001).CONCLUSIONCollectively, the findings reveal a previously unrecognized link between lipid markers of impaired mitochondrial β-oxidation and enhanced lipogenesis and DKD progression in individuals with preserved GFR. Renal acetyl-CoA carboxylase activation accompanies these lipidomic changes and suggests that it may be the underlying mechanism linking lipid abnormalities to DKD progression.TRIAL REGISTRATIONClinicalTrials.gov, NCT00340678.FUNDINGNIH R24DK082841, K08DK106523, R03DK121941, P30DK089503, P30DK081943, and P30DK020572.
在本研究中,我们确定了目前尚未明确的早期 2 型糖尿病肾病(DKD)进展的脂质组学预测因子。
这项纵向研究纳入了 92 名美国印第安人 2 型糖尿病患者。基线时,使用基于碘海醇的肾小球滤过率(GFR)至少为 90ml/min 时的血清样本,通过质谱法对血清脂质(406 种来自 18 类)进行定量。使用 Affymetrix GeneChip 阵列测量肾脏转录表达。DKD 进展定义为随访期间 GFR 至少下降 40%。
参与者的平均年龄为 45±9 岁,中位尿白蛋白/肌酐比值为 43(四分位间距 11-144)。32 名进展者的多不饱和三酰基甘油(TAG)相对丰度显著升高,而 C16-C20 酰基辅酶 A(AC)丰度降低(P<0.001)。在 Cox 回归模型中,不饱和游离脂肪酸和磷脂酰乙醇胺的主要效应项以及白蛋白尿分类中 C16-C20 AC 和短-低-双键 TAG 的交互项独立预测了 DKD 进展。乙酰辅酶 A 羧化酶编码基因(ACACA)的肾脏表达与肾小球部分的二酰甘油(r=0.36,P=0.006)和肾小管间质部分的低双键 TAG 相关(r=0.52,P<0.001)。
总的来说,这些发现揭示了在 GFR 正常的个体中,受损的线粒体β-氧化和增强的脂肪生成的脂质标志物与 DKD 进展之间以前未被认识到的联系。肾脏乙酰辅酶 A 羧化酶的激活伴随着这些脂质组学变化,表明它可能是将脂质异常与 DKD 进展联系起来的潜在机制。
ClinicalTrials.gov,NCT00340678。
NIH R24DK082841、K08DK106523、R03DK121941、P30DK089503、P30DK081943 和 P30DK020572。